Filtered By:
Condition: Stroke
Drug: Actos
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 156 results found since Jan 2013.
Efficacy of Lower Doses of Pioglitazone after Stroke or Transient Ischemic Attack In Patients with Insulin Resistance
CONCLUSIONS: Lower doses of pioglitazone appear to confer much of the benefit with less adverse effects than the full dose. Further study is needed to confirm these findings so that clinicians may optimize dosing of this secondary prevention strategy in stroke patients. This article is protected by copyright. All rights reserved.PMID:35253334 | DOI:10.1111/dom.14687
Source: Atherosclerosis - March 7, 2022 Category: Cardiology Authors: J David Spence Catherine Viscoli Walter N Kernan Lawrence H Young Karen Furie Ralph DeFronzo Muhammad Abdul-Ghani Paresh Dandona Silvio E Inzucchi Source Type: research
Hormesis and Endothelial Progenitor Cells
Dose Response. 2022 Feb 23;20(1):15593258211068625. doi: 10.1177/15593258211068625. eCollection 2022 Jan-Mar.ABSTRACTHormetic-biphasic dose response relationships are reported herein for human endothelial progenitor cells involving estradiol, nicotine, the anti-diabetic agent pioglitazone, resveratrol, and progesterone. In general, these studies demonstrate the capacity of these agents to enhance EPC proliferation and angiogenesis functional applications, having a focus on repairing endothelial tissue damage due to acute injury (e.g., stroke), as well as damage from chronic conditions (e.g., atherosclerosis) and normal agi...
Source: Dose Response - February 28, 2022 Category: Drugs & Pharmacology Authors: Edward J Calabrese Source Type: research
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
CONCLUSION: In this real-world data, the risk of stroke was comparable in T2DM patients treated with SGLT-2i or TZD.PMID:35130688 | DOI:10.4093/dmj.2021.0160
Source: Diabetes and Metabolism Journal - February 8, 2022 Category: Endocrinology Authors: Seung Eun Lee Hyewon Nam Han Seok Choi Hoseob Kim Dae-Sung Kyoung Kyoung-Ah Kim Source Type: research
PPAR agonists for the treatment of cardiovascular disease in patients with Diabetes
Conclusions: According to this study, Pioglitazone treatment in type 2 diabetes patients and hypersensitive Ischemic stroke patients is linked to minor ischemic stroke which is recurrent in Asian people. Pioglitazone and the telmisartan treatment have an increasing pleiotropic effect related to the higher PPAR- gamma effects. Further research needs to be conducted with the PPAR mechanism ' s details to confirm the PPAR effect on Ischemic stroke treatment. [Ethiop. J. Health Dev. 2021; 35(3): 249-257]Keywords: PPAR agonist, Dyslipidaemia, Thiazolidinediones, Type 2 diabetes, Pioglitazone, PPAR-alpha, PPAR-gamma, Insulin resistance, Alecardio.
Source: Ethiopian Journal of Health Development - November 25, 2021 Category: African Health Authors: Zheng Xia, Guo Lixia, Zhang Zhijun Source Type: research
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case –control study
Pioglitazone use is known to be associated with a reduced risk of recurrent stroke in patients with diabetes mellitus (DM) who have a history of stroke. However, it is unclear whether this benefit extends to p...
Source: Cardiovascular Diabetology - July 27, 2021 Category: Cardiology Authors: Junghee Ha, Dong-Woo Choi, Keun You Kim, Chung Mo Nam and Eosu Kim Tags: Original investigation Source Type: research
Stroke Prevention: Little-Known and Neglected Aspects
Combining available therapies has the potential to reduce the risk of stroke by 80% or more. A comprehensive review of all aspects of stroke prevention would be very lengthy; in this narrative review, we focus on some aspects of stroke prevention that are little-known and/or neglected. These include the following: (1) implementation of a Mediterranean diet; (2) B vitamins to lower homocysteine; (3) coordinated approaches to smoking cessation; (4) intensive lipid-lowering therapy; (5) lipid lowering in the elderly; (6) physiologically individualized therapy for hypertension based on renin/aldosterone phenotyping; (7) avoidi...
Source: Cerebrovascular Diseases - May 27, 2021 Category: Neurology Source Type: research
Mild traumatic brain injury increases vulnerability to cerebral ischemia in mice
Exp Neurol. 2021 May 13:113765. doi: 10.1016/j.expneurol.2021.113765. Online ahead of print.ABSTRACTRecent studies have reported that TBI is an independent risk factor for subsequent stroke. Here, we tested the hypothesis that TBI would exacerbate experimental stroke outcomes via alternations in neuroimmune and neurometabolic function. We performed a mild closed-head TBI and then one week later induced an experimental stroke in adult male mice. Mice that had previously experienced TBI exhibited larger infarcts, greater functional deficits, and more pronounced neuroinflammatory responses to stroke. We hypothesized that impa...
Source: Experimental Neurology - May 16, 2021 Category: Neurology Authors: Zachary M Weil Kate Karelina Bailey Whitehead Ruth Velazquez-Cruz Robin Oliverio Mark Pinti Divine C Nwafor Samuel Nicholson Julie A Fitzgerald John Hollander Candice M Brown Ning Zhang A Courtney DeVries Source Type: research
Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis
It is well established that diabetes mellitus type 2 (T2DM) is associated with increased risk of cardiovascular disease, including ischemic stroke. Among past antidiabetic agents, only pioglitazone and glucagon-like peptide 1 receptor agonists (GLP-1RA) have been shown to decrease the risk of stroke.1-5 Similarly, sodium-glucose cotransporter-2 inhibitors (SGLT2i) were expected to reduce the risk of stroke, considering their blood pressure lowering and neuroprotective effects demonstrated by experimental studies.
Source: Journal of Stroke and Cerebrovascular Diseases - March 10, 2021 Category: Neurology Authors: Fotios Barkas, Sebastian Filippas Ntekouan, Evangelos Liberopoulos, Theodosios Filippatos, Haralampos Milionis Source Type: research
